Physician profile
Richard Stone
NPI 1508178336
$3,224.03
in general payments reported to CMS, 2019-2025
22 companies · $62.17 in 2025
The $62.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.13 · 2020: $87.03 · 2021: $2,592 · 2022: $213 · 2023: $170 · 2024: $66.38 · 2025: $62.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,500.00 | 2021 | |
| Lilly USA, LLC | $161.20 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $142.45 | 2021-2022 | |
| Glaxosmithkline, LLC. | $51.15 | 2022-2023 | Arexvy, Shingrix |
| Smith+Nephew, INC. | $50.24 | 2019-2020 | |
| Novo Nordisk INC | $39.54 | 2022-2025 | |
| Amgen INC. | $33.85 | 2020-2023 | Repatha |
| Pfizer INC. | $28.27 | 2022-2023 | |
| Axsome Therapeutics, INC. | $19.73 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $17.80 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.63 | 2023 | Quviviq |
| Astellas Pharma US INC | $17.56 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $16.71 | 2024 | |
| Xeris Pharmaceuticals, INC. | $15.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.82 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $14.70 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $14.31 | 2024 | (Ck4) Mcot |
| Biohaven Pharmaceutical Holding Company LTD. | $13.79 | 2022 | |
| Amarin Pharma, INC. | $13.74 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.08 | 2023 | Farxiga |
| Dexcom, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.